TCGA-97-8177, TCGA-97-8177SENT_1,"SURGICAL PATHOLOGY REPORT","{SURGICAL,PATHOLOGY,REPORT}","{surgical,pathology,report}","{JJ,NN,NN}","{3,3,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_2,"COLLECTION DATE : ?","{COLLECTION,DATE,:,?}","{COLLECTION,DATE,:,?}","{NNP,NNP,:,CD}","{2,0,0,2}","{}"
TCGA-97-8177, TCGA-97-8177SENT_3,"SPECIIVIENS : 1 .","{SPECIIVIENS,:,1,.}","{SPECIIVIENS,:,1,.}","{NNP,:,CD,.}","{0,0,1,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_4,"STATION 7 LYMPH NODE 2 .","{STATION,7,LYMPH,NODE,2,.}","{station,7,lymph,node,2,.}","{NN,CD,NN,NN,CD,.}","{4,4,4,0,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_5,"STATION 11 LYMPH NODE 3 .","{STATION,11,LYMPH,NODE,3,.}","{station,11,lymph,node,3,.}","{NN,CD,NN,NN,CD,.}","{4,4,4,0,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_6,"STATION 12 LYMPH NODE 4 .","{STATION,12,LYMPH,NODE,4,.}","{station,12,lymph,node,4,.}","{NN,CD,NN,NN,CD,.}","{4,4,4,0,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_7,"LUNG LEFT LOWER LOBECTOMY 5 .","{LUNG,LEFT,LOWER,LOBECTOMY,5,.}","{lung,LEFT,LOWER,LOBECTOMY,5,.}","{NN,NNP,NNP,NNP,CD,.}","{0,5,5,1,5,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_8,"STATION 5 LYMPH NODE SEE ADDENDUM","{STATION,5,LYMPH,NODE,SEE,ADDENDUM}","{station,5,lymph,node,see,addendum}","{NN,CD,NN,NN,VBP,NN}","{4,4,4,0,4,5}","{}"
TCGA-97-8177, TCGA-97-8177SENT_9,"Reason For Addendum # 1 : Special Stains Results Reason For Addendum # 2 : Molecular Studies Reason For Addendum # 3 : Molecular Studies DIAGNOSIS : 1 .","{Reason,For,Addendum,#,1,:,Special,Stains,Results,Reason,For,Addendum,#,2,:,Molecular,Studies,Reason,For,Addendum,#,3,:,Molecular,Studies,DIAGNOSIS,:,1,.}","{reason,for,Addendum,#,1,:,special,stain,result,reason,for,Addendum,#,2,:,molecular,study,reason,for,Addendum,#,3,:,molecular,study,diagnosis,:,1,.}","{NN,IN,NNP,#,CD,:,JJ,NNS,NNS,NN,IN,NNP,#,CD,:,JJ,NNS,NN,IN,NNP,#,CD,:,JJ,NNS,NNS,:,CD,.}","{0,1,2,5,3,0,9,9,1,11,9,11,14,12,0,18,18,1,18,19,22,20,0,25,26,1,0,26,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_10,"LYMPH NODE STATION 7 : BIOPSY - ADIPOSE TISSUE NEGATIVE FOR CARCINOMA .","{LYMPH,NODE,STATION,7,:,BIOPSY,-,ADIPOSE,TISSUE,NEGATIVE,FOR,CARCINOMA,.}","{lymph,node,station,7,:,biopsy,-,adipose,tissue,NEGATIVE,for,CARCINOMA,.}","{NN,NN,NN,CD,:,NN,:,NN,NN,NNP,IN,NNP,.}","{2,0,2,4,0,2,0,10,7,2,0,12,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_11,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_12,"LYMPH NODE STATION 11 : BIOPSY - FRAGMENTS OF ANTHRACOTIC LYMPH NODE NEGATIVE FOR CARCINOMA .","{LYMPH,NODE,STATION,11,:,BIOPSY,-,FRAGMENTS,OF,ANTHRACOTIC,LYMPH,NODE,NEGATIVE,FOR,CARCINOMA,.}","{lymph,node,station,11,:,biopsy,-,fragment,of,ANTHRACOTIC,LYMPH,NODE,NEGATIVE,for,CARCINOMA,.}","{NN,NN,NN,CD,:,NN,:,NNS,IN,NNP,NNP,NNP,NNP,IN,NNP,.}","{2,0,2,4,0,2,0,2,0,13,13,9,13,0,15,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_13,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_14,"LYMPH NODE STATION 12 : BIOPSY - FRAGMENTS OF ANTHRACOTIC LYMPH NODE NEGATIVE FOR CARCINOMA .","{LYMPH,NODE,STATION,12,:,BIOPSY,-,FRAGMENTS,OF,ANTHRACOTIC,LYMPH,NODE,NEGATIVE,FOR,CARCINOMA,.}","{lymph,node,station,12,:,biopsy,-,fragment,of,ANTHRACOTIC,LYMPH,NODE,NEGATIVE,for,CARCINOMA,.}","{NN,NN,NN,CD,:,NN,:,NNS,IN,NNP,NNP,NNP,NNP,IN,NNP,.}","{2,0,2,4,0,2,0,2,0,13,13,9,13,0,15,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_15,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_16,"LUNG LEFT LOWER LOBE : LOBECTOMY - ADENOCARCINOMA OF MIXED SUB-TYPE ( 4 CM ) MODERATELY DIFFERENTIATED ( SEE SUMMARY ) .","{LUNG,LEFT,LOWER,LOBE,:,LOBECTOMY,-,ADENOCARCINOMA,OF,MIXED,SUB-TYPE,(,4,CM,),MODERATELY,DIFFERENTIATED,(,SEE,SUMMARY,),.}","{lung,LEFT,LOWER,LOBE,:,lobectomy,-,adenocarcinoma,of,MIXED,SUB-TYPE,(,4,cm,),moderately,differentiate,(,see,summary,),.}","{NN,NNP,NNP,NNP,:,NN,:,NN,IN,NNP,NNP,NN,CD,NN,NN,RB,VBN,CD,VBP,NN,NN,.}","{0,1,6,1,0,1,0,22,0,13,10,17,17,17,13,20,10,20,1,24,22,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_17,"- BRONCHOVASCULAR MARGIN NEGATIVE FOR CARCINOMA .","{-,BRONCHOVASCULAR,MARGIN,NEGATIVE,FOR,CARCINOMA,.}","{-,bronchovascular,margin,NEGATIVE,for,CARCINOMA,.}","{:,NN,NN,NNP,IN,NNP,.}","{0,3,0,3,0,3,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_18,"- BENIGN PERIBRONCHIAL ANTHRACOTIC LYMPH NODES NEGATIVE FOR CARCINOMA .","{-,BENIGN,PERIBRONCHIAL,ANTHRACOTIC,LYMPH,NODES,NEGATIVE,FOR,CARCINOMA,.}","{-,benign,peribronchial,anthracotic,lymph,node,NEGATIVE,for,CARCINOMA,.}","{:,JJ,JJ,NN,NN,NNS,NNP,IN,NNP,.}","{0,6,6,6,6,0,6,0,6,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_19,"5 .","{5,.}","{5,.}","{CD,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_20,"LYMPH NODE STATION 5 : BIOPSY - FRAGMENTS OF ANTHRACOTIC LYMPH NODE NEGATIVE FOR CARCINOMA .","{LYMPH,NODE,STATION,5,:,BIOPSY,-,FRAGMENTS,OF,ANTHRACOTIC,LYMPH,NODE,NEGATIVE,FOR,CARCINOMA,.}","{lymph,node,station,5,:,biopsy,-,fragment,of,ANTHRACOTIC,LYMPH,NODE,NEGATIVE,for,CARCINOMA,.}","{NN,NN,NN,CD,:,NN,:,NNS,IN,NNP,NNP,NNP,NNP,IN,NNP,.}","{2,0,2,4,0,2,0,2,0,13,13,9,13,0,15,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_21,"Specimens : 1 : STATION 7 LYMPH NODE 2 : STATION 11 LYMPH NODE 3 : STATION 12 LYMPH NODE 4 : LUNG LEFT LOWER LOBECTOMY 5 : STATION 5 LYMPH NODE","{Specimens,:,1,:,STATION,7,LYMPH,NODE,2,:,STATION,11,LYMPH,NODE,3,:,STATION,12,LYMPH,NODE,4,:,LUNG,LEFT,LOWER,LOBECTOMY,5,:,STATION,5,LYMPH,NODE}","{specimen,:,1,:,station,7,lymph,node,2,:,station,11,lymph,node,3,:,station,12,LYMPH,NODE,4,:,lung,LEFT,LOWER,LOBECTOMY,5,:,station,5,lymph,node}","{NNS,:,CD,:,NN,CD,NN,NN,CD,:,NN,CD,NN,NN,CD,:,NN,CD,NNP,NNP,CD,:,NN,NNP,NNP,NNP,CD,:,NN,CD,NN,NN}","{0,0,1,0,8,8,8,3,8,0,14,14,14,8,14,0,20,20,20,8,20,0,8,27,27,23,27,0,8,33,33,30}","{}"
TCGA-97-8177, TCGA-97-8177SENT_22,"LUNG : Resection SPECIMEN Specimen : Lobe ( s ) of lung ( specify ) left lower Procedure : Lobectomy Specimen Laterality : Left Tumor Site : Lower lobe Tumor Focality : Unifocal TUMOR Histologic Type : Adenocarcinoma mixed subtype Histologic Grade : G2 : Moderately differentiated EXTENT Tumor Size : Greatest dimension ( cm ) 4cm Additional Dimension ( cm ) : 4cm X 3cm MARGINS Bronchial Margin Bronchial Margin Involvement by Invasive Carcinoma : Uninvolved by invasive carcinoma Bronchial Margin Involvement by Squamous Cell Carcinoma in situ ( CIS ) : Squamous cell carcinoma in situ ( CIS ) not identified at bronchial margin Vascular Margin : Uninvolved by invasive carcinoma ACCESSORY FINDINGS Lymph-Vascular Invasion : Present SPECIAL STUDIES Epidermal Growth Factor Receptor ( EGFR ) Analysis Results ( specify method ) : to follow KRAS Mutational Analysis ( specify results ) : to follow STAGE ( pTNM ) Primary Tumor ( pT ) : pT2a : Tumor greater than 3 cm but 5 cm or less in greatest dimension surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus ( i.e. not in the main bronchus ) ; or Tumor 5 cm or less in greatest dimension with any of the following features of extent : involves main bronchus 2 cm or more distal to the carina ; invades the visceral pleura ; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung Regional Lymph Nodes ( pN ) pNo : No regional lymph node metastasis ADDITIONAL NON-TUMOR Additional Pathologic Finding ( s ) : Emphysema small intraparenchymal scar and meningoethial-like nodule Comment ( s ) : The adenocarcinoma is of mixed subtype displaying papillary and acinar patterns and is associated with scar .","{LUNG,:,Resection,SPECIMEN,Specimen,:,Lobe,(,s,),of,lung,(,specify,),left,lower,Procedure,:,Lobectomy,Specimen,Laterality,:,Left,Tumor,Site,:,Lower,lobe,Tumor,Focality,:,Unifocal,TUMOR,Histologic,Type,:,Adenocarcinoma,mixed,subtype,Histologic,Grade,:,G2,:,Moderately,differentiated,EXTENT,Tumor,Size,:,Greatest,dimension,(,cm,),4cm,Additional,Dimension,(,cm,),:,4cm,X,3cm,MARGINS,Bronchial,Margin,Bronchial,Margin,Involvement,by,Invasive,Carcinoma,:,Uninvolved,by,invasive,carcinoma,Bronchial,Margin,Involvement,by,Squamous,Cell,Carcinoma,in,situ,(,CIS,),:,Squamous,cell,carcinoma,in,situ,(,CIS,),not,identified,at,bronchial,margin,Vascular,Margin,:,Uninvolved,by,invasive,carcinoma,ACCESSORY,FINDINGS,Lymph-Vascular,Invasion,:,Present,SPECIAL,STUDIES,Epidermal,Growth,Factor,Receptor,(,EGFR,),Analysis,Results,(,specify,method,),:,to,follow,KRAS,Mutational,Analysis,(,specify,results,),:,to,follow,STAGE,(,pTNM,),Primary,Tumor,(,pT,),:,pT2a,:,Tumor,greater,than,3,cm,but,5,cm,or,less,in,greatest,dimension,surrounded,by,lung,or,visceral,pleura,without,bronchoscopic,evidence,of,invasion,more,proximal,than,the,lobar,bronchus,(,i.e.,not,in,the,main,bronchus,),;,or,Tumor,5,cm,or,less,in,greatest,dimension,with,any,of,the,following,features,of,extent,:,involves,main,bronchus,2,cm,or,more,distal,to,the,carina,;,invades,the,visceral,pleura,;,associated,with,atelectasis,or,obstructive,pneumonitis,that,extends,to,the,hilar,region,but,does,not,involve,the,entire,lung,Regional,Lymph,Nodes,(,pN,),pNo,:,No,regional,lymph,node,metastasis,ADDITIONAL,NON-TUMOR,Additional,Pathologic,Finding,(,s,),:,Emphysema,small,intraparenchymal,scar,and,meningoethial-like,nodule,Comment,(,s,),:,The,adenocarcinoma,is,of,mixed,subtype,displaying,papillary,and,acinar,patterns,and,is,associated,with,scar,.}","{lung,:,Resection,SPECIMEN,Specimen,:,lobe,(,s,),of,lung,(,specify,),leave,lower,Procedure,:,Lobectomy,Specimen,Laterality,:,leave,tumor,site,:,lower,lobe,tumor,focality,:,unifocal,tumor,histologic,type,:,adenocarcinoma,mixed,subtype,histologic,Grade,:,g2,:,moderately,differentiate,EXTENT,tumor,size,:,greatest,dimension,(,cm,),4cm,additional,dimension,(,cm,),:,4cm,x,3cm,margin,bronchial,margin,bronchial,margin,involvement,by,Invasive,Carcinoma,:,uninvolved,by,invasive,carcinoma,bronchial,margin,involvement,by,Squamous,Cell,Carcinoma,in,situ,(,ci,),:,squamous,cell,carcinoma,in,situ,(,ci,),not,identify,at,bronchial,margin,vascular,margin,:,uninvolve,by,invasive,carcinoma,accessory,finding,lymph-vascular,Invasion,:,present,special,study,epidermal,growth,factor,receptor,(,egfr,),analysis,result,(,specify,method,),:,to,follow,KRAS,mutational,analysis,(,specify,result,),:,to,follow,STAGE,(,ptnm,),primary,tumor,(,pt,),:,pt2a,:,tumor,greater,than,3,cm,but,5,cm,or,less,in,greatest,dimension,surround,by,lung,or,visceral,pleuron,without,bronchoscopic,evidence,of,invasion,more,proximal,than,the,lobar,bronchus,(,i.e.,not,in,the,main,bronchus,),;,or,tumor,5,cm,or,less,in,greatest,dimension,with,any,of,the,follow,feature,of,extent,:,involve,main,bronchus,2,cm,or,more,distal,to,the,carina,;,invade,the,visceral,pleuron,;,associate,with,atelectasis,or,obstructive,pneumonitis,that,extend,to,the,hilar,region,but,do,not,involve,the,entire,lung,Regional,Lymph,Nodes,(,pn,),pno,:,no,regional,lymph,node,metastasis,additional,non-tumor,additional,pathologic,find,(,s,),:,Emphysema,small,intraparenchymal,scar,and,meningoethial-like,nodule,comment,(,s,),:,the,adenocarcinoma,be,of,mixed,subtype,display,papillary,and,acinar,pattern,and,be,associate,with,scar,.}","{NN,:,NNP,NNP,NNP,:,NN,CD,NNS,CD,IN,NN,NN,VB,RB,VBN,JJR,NNP,:,NNP,NNP,NNP,:,VBN,NN,NN,:,JJR,NN,NN,NN,:,JJ,NN,JJ,NN,:,NN,JJ,NN,JJ,NNP,:,NN,:,RB,VBN,NNP,NN,NN,:,JJS,NN,CD,NN,NN,CD,JJ,NN,CD,NN,NN,:,CD,NN,CD,NNS,JJ,NN,JJ,NN,NN,IN,NNP,NNP,:,JJ,IN,JJ,NN,JJ,NN,NN,IN,NNP,NNP,NNP,FW,FW,FW,NN,CD,:,JJ,NN,NN,FW,FW,FW,NN,CD,RB,VBN,IN,JJ,NN,JJ,NN,:,VBN,IN,JJ,NN,NN,NNS,JJ,NNP,:,JJ,JJ,NNS,JJ,NN,NN,NN,CD,NN,CD,NN,NNS,VBP,VB,NN,NN,:,TO,VB,NNP,JJ,NN,NN,VB,NNS,CD,:,TO,VB,NNP,CD,NN,CD,JJ,NN,CD,NN,CD,:,NN,:,NN,JJR,IN,CD,NN,CC,CD,NN,CC,JJR,IN,JJS,NN,VBN,IN,NN,CC,JJ,NN,IN,JJ,NN,IN,NN,RBR,JJ,IN,DT,JJ,NN,CD,FW,RB,IN,DT,JJ,NN,NN,:,CC,NN,CD,NN,CC,JJR,IN,JJS,NN,IN,DT,IN,DT,VBG,NNS,IN,NN,:,VBZ,JJ,NNS,CD,NN,CC,JJR,JJ,TO,DT,NN,:,VBZ,DT,JJ,NN,:,VBN,IN,NN,CC,JJ,NN,WDT,VBZ,TO,DT,JJ,NN,CC,VBZ,RB,VB,DT,JJ,NN,NNP,NNP,NNP,CD,NN,CD,NN,:,DT,JJ,NN,NN,NN,JJ,NN,JJ,JJ,VBG,NN,NNS,CD,:,NNP,JJ,JJ,NN,CC,JJ,NN,NN,CD,NNS,CD,:,DT,NN,VBZ,IN,JJ,NN,VBG,NN,CC,JJ,NNS,CC,VBZ,VBN,IN,NN,.}","{309,0,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,0,309,309,309,0,309,309,309,309,0,309,309,309,309,0,309,309,309,309,309,0,309,0,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,0,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,0,309,309,309,309,309,309,309,309,309,309,309,309,309,309,309,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_23,"Although predominantly moderately differentiated small foci of pleomorphic poorly differentiated tumor cells are present .","{Although,predominantly,moderately,differentiated,small,foci,of,pleomorphic,poorly,differentiated,tumor,cells,are,present,.}","{although,predominantly,moderately,differentiate,small,focus,of,pleomorphic,poorly,differentiate,tumor,cell,be,present,.}","{IN,RB,RB,VBN,JJ,NNS,IN,JJ,RB,VBN,NN,NNS,VBP,JJ,.}","{4,4,4,15,7,15,0,7,11,9,13,11,15,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_24,"A TTF1 immunostain is positive compatible with pulmonary origin .","{A,TTF1,immunostain,is,positive,compatible,with,pulmonary,origin,.}","{a,ttf1,immunostain,be,positive,compatible,with,pulmonary,origin,.}","{DT,NN,NN,VBZ,JJ,JJ,IN,JJ,NN,.}","{3,3,5,5,0,5,0,10,7,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_25,"Venous invasion is present .","{Venous,invasion,is,present,.}","{venous,invasion,be,present,.}","{JJ,NN,VBZ,JJ,.}","{2,4,4,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_26,"Perineural infiltration is seen .","{Perineural,infiltration,is,seen,.}","{perineural,infiltration,be,see,.}","{JJ,NN,VBZ,VBN,.}","{2,4,4,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_27,"Pathologist","{Pathologist}","{pathologist}","{NN}","{0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_28,"CLINICAL HISTORY AND PRE ? OPERATIVE DIAGNOSIS : Lung cancer","{CLINICAL,HISTORY,AND,PRE,?,OPERATIVE,DIAGNOSIS,:,Lung,cancer}","{clinical,history,and,pre,?,OPERATIVE,DIAGNOSIS,:,lung,cancer}","{JJ,NN,CC,NN,CD,NNP,NNP,:,NN,NN}","{2,0,0,2,4,7,2,0,10,7}","{}"
TCGA-97-8177, TCGA-97-8177SENT_29,"MACROSCOPIC DESCRIPTION : The specimen is received fresh in five parts each labeled with the patient ? s name .","{MACROSCOPIC,DESCRIPTION,:,The,specimen,is,received,fresh,in,five,parts,each,labeled,with,the,patient,?,s,name,.}","{macroscopic,description,:,the,specimen,be,receive,fresh,in,five,part,each,label,with,the,patient,?,s,name,.}","{JJ,NN,:,DT,NN,VBZ,VBN,JJ,IN,CD,NNS,DT,VBN,IN,DT,NN,CD,NNS,NN,.}","{2,0,0,5,7,7,2,7,0,11,7,7,13,0,17,14,19,17,19,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_30,"1 .","{1,.}","{1,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_31,"Part one is labeled ? station 7 lymph node ? .","{Part,one,is,labeled,?,station,7,lymph,node,?,.}","{Part,one,be,label,?,station,7,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,.}","{4,1,4,0,10,10,10,10,10,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_32,"It consists of a 0.7 X 0.6 X 0.3 cm irregular portion of pink yellow soft adipose tissue .","{It,consists,of,a,0.7,X,0.6,X,0.3,cm,irregular,portion,of,pink,yellow,soft,adipose,tissue,.}","{it,consist,of,a,0.7,x,0.6,x,0.3,cm,irregular,portion,of,pink,yellow,soft,adipose,tissue,.}","{PRP,VBZ,IN,DT,CD,NN,CD,NN,CD,NN,JJ,NN,IN,JJ,JJ,JJ,NN,NN,.}","{2,0,0,6,6,2,6,6,8,12,12,2,0,18,18,18,18,12,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_33,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_34,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_35,"Part two is labeled ? station ll lymph node ? .","{Part,two,is,labeled,?,station,ll,lymph,node,?,.}","{Part,two,be,label,?,station,ll,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,NN,NN,NN,NN,.}","{4,1,4,0,7,7,4,10,10,7,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_36,"It consists of a 1.5 X l X 0.6 cm aggregate of black soft rubbery anthracotic lymphoid tissue .","{It,consists,of,a,1.5,X,l,X,0.6,cm,aggregate,of,black,soft,rubbery,anthracotic,lymphoid,tissue,.}","{it,consist,of,a,1.5,x,l,x,0.6,cm,aggregate,of,black,soft,rubbery,anthracotic,lymphoid,tissue,.}","{PRP,VBZ,IN,DT,CD,NN,NN,NN,CD,NN,NN,IN,JJ,JJ,JJ,JJ,JJ,NN,.}","{2,0,0,6,6,11,11,11,11,11,2,0,18,18,18,18,18,11,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_37,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_38,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_39,"Part three is labeled ? station 12 lymph node ? .","{Part,three,is,labeled,?,station,12,lymph,node,?,.}","{Part,three,be,label,?,station,12,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,.}","{4,1,4,0,10,10,10,10,10,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_40,"It consists of l X 0.6 X 0.2 cm aggregate of black soft rubbery anthracotic lymphoid tissue admixed with pink yellow soft adipose tissue .","{It,consists,of,l,X,0.6,X,0.2,cm,aggregate,of,black,soft,rubbery,anthracotic,lymphoid,tissue,admixed,with,pink,yellow,soft,adipose,tissue,.}","{it,consist,of,l,x,0.6,x,0.2,cm,aggregate,of,black,soft,rubbery,anthracotic,lymphoid,tissue,admix,with,pink,yellow,soft,adipose,tissue,.}","{PRP,VBZ,IN,NN,NN,CD,NN,CD,NN,NN,IN,JJ,JJ,JJ,JJ,JJ,NN,VBN,IN,JJ,JJ,JJ,NN,NN,.}","{2,0,0,5,2,5,10,10,10,2,0,17,17,17,17,17,10,17,0,24,24,24,24,18,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_41,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_42,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_43,"Part four is labeled ? left lower lobectomy ? .","{Part,four,is,labeled,?,left,lower,lobectomy,?,.}","{Part,four,be,label,?,leave,lower,lobectomy,?,.}","{NNP,CD,VBZ,VBN,CD,VBD,JJR,NN,NN,.}","{4,1,4,0,4,5,9,9,6,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_44,"It consists of a left lower lobectomy specimen measuring 15 X 13 X 5 cm .","{It,consists,of,a,left,lower,lobectomy,specimen,measuring,15,X,13,X,5,cm,.}","{it,consist,of,a,leave,lower,lobectomy,specimen,measure,15,x,13,x,5,cm,.}","{PRP,VBZ,IN,DT,VBN,JJR,NN,NN,VBG,CD,NN,CD,NN,CD,NN,.}","{2,0,0,2,4,8,8,5,5,11,13,13,9,15,13,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_45,"The bronchial margin is ( 1.6 cm diameter ) and vascular margin at the hilum are grossly free of tumor .","{The,bronchial,margin,is,(,1.6,cm,diameter,),and,vascular,margin,at,the,hilum,are,grossly,free,of,tumor,.}","{the,bronchial,margin,be,(,1.6,cm,diameter,),and,vascular,margin,at,the,hilum,be,grossly,free,of,tumor,.}","{DT,JJ,NN,VBZ,JJ,CD,NN,NN,NN,CC,JJ,NN,IN,DT,NN,VBP,RB,JJ,IN,NN,.}","{3,3,7,7,7,5,0,9,18,0,12,18,0,15,9,18,18,7,0,18,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_46,"The pleura is grey ? pink glistening and mottled ; a 3 cm puckered area is noted at the upper outer aspect of the lobe ( inked in black ) .","{The,pleura,is,grey,?,pink,glistening,and,mottled,;,a,3,cm,puckered,area,is,noted,at,the,upper,outer,aspect,of,the,lobe,(,inked,in,black,),.}","{the,pleuron,be,grey,?,pink,glisten,and,mottle,;,a,3,cm,puckered,area,be,note,at,the,upper,outer,aspect,of,the,lobe,(,ink,in,black,),.}","{DT,NN,VBZ,JJ,NN,NN,VBG,CC,VBN,:,DT,CD,NN,JJ,NN,VBZ,VBN,IN,DT,JJ,JJ,NN,IN,DT,NN,NN,VBN,IN,JJ,NN,.}","{2,6,6,6,6,0,6,0,8,0,16,14,15,16,18,18,6,0,23,23,23,18,0,27,27,23,27,0,31,28,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_47,"A staple line measures 5 cm in length which is shaved and the pleura around it is inked in black .","{A,staple,line,measures,5,cm,in,length,which,is,shaved,and,the,pleura,around,it,is,inked,in,black,.}","{a,staple,line,measure,5,cm,in,length,which,be,shave,and,the,pleuron,around,it,be,ink,in,black,.}","{DT,JJ,NN,NNS,CD,NN,IN,NN,WDT,VBZ,VBN,CC,DT,NN,IN,PRP,VBZ,VBN,IN,JJ,.}","{4,4,4,19,6,4,0,4,12,12,8,0,15,19,0,15,19,0,0,19,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_48,"Beneath the puckered area 1.2 cm from the bronchial resection margin ; a 4 X 4 X 3 cm grey ? white finn tumor with ill ? defined borders is noted .","{Beneath,the,puckered,area,1.2,cm,from,the,bronchial,resection,margin,;,a,4,X,4,X,3,cm,grey,?,white,finn,tumor,with,ill,?,defined,borders,is,noted,.}","{beneath,the,puckered,area,1.2,cm,from,the,bronchial,resection,margin,;,a,4,x,4,x,3,cm,grey,?,white,finn,tumor,with,ill,?,define,border,be,note,.}","{IN,DT,JJ,NN,CD,NN,IN,DT,JJ,NN,NN,:,DT,CD,NN,CD,NN,CD,NN,NN,CD,JJ,NN,NN,IN,JJ,NN,VBN,NNS,VBZ,VBN,.}","{0,4,4,32,7,32,0,12,12,12,7,0,21,21,21,21,21,21,21,25,25,25,25,12,0,28,25,12,29,32,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_49,"The remainder of the parenchyma is pink ? red blotchy and crepitant .","{The,remainder,of,the,parenchyma,is,pink,?,red,blotchy,and,crepitant,.}","{the,remainder,of,the,parenchyma,be,pink,?,red,blotchy,and,crepitant,.}","{DT,NN,IN,DT,NN,VBZ,JJ,NN,NN,JJ,CC,JJ,.}","{2,9,0,5,2,9,9,9,0,9,0,9,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_50,"Multiple peribronchial anthracotic firm lymph nodes ranging from 0.2 up to 0.7 cm in greatest dimension are identified from the hilar area .","{Multiple,peribronchial,anthracotic,firm,lymph,nodes,ranging,from,0.2,up,to,0.7,cm,in,greatest,dimension,are,identified,from,the,hilar,area,.}","{multiple,peribronchial,anthracotic,firm,lymph,node,range,from,0.2,up,to,0.7,cm,in,greatest,dimension,be,identify,from,the,hilar,area,.}","{JJ,JJ,JJ,NN,NN,NNS,VBG,IN,CD,IN,TO,CD,NN,IN,JJS,NN,VBP,VBN,IN,DT,JJ,NN,.}","{6,6,6,6,6,20,6,0,8,8,0,14,11,0,17,8,20,0,0,24,24,20,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_51,"Representative sections are submitted .","{Representative,sections,are,submitted,.}","{Representative,section,be,submit,.}","{NNP,NNS,VBP,VBN,.}","{2,4,4,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_52,"5 .","{5,.}","{5,.}","{CD,.}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_53,"Part five is labeled ? station 5 lymph node ? .","{Part,five,is,labeled,?,station,5,lymph,node,?,.}","{Part,five,be,label,?,station,5,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,.}","{4,1,4,0,10,10,10,10,10,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_54,"It consists of a 2.3 X 1.8 X 0.8 cm aggregate of black soft rubbery anthracotic lymphoid tissue admixed with yellow soft adipose tissue .","{It,consists,of,a,2.3,X,1.8,X,0.8,cm,aggregate,of,black,soft,rubbery,anthracotic,lymphoid,tissue,admixed,with,yellow,soft,adipose,tissue,.}","{it,consist,of,a,2.3,x,1.8,x,0.8,cm,aggregate,of,black,soft,rubbery,anthracotic,lymphoid,tissue,admix,with,yellow,soft,adipose,tissue,.}","{PRP,VBZ,IN,DT,CD,NN,CD,NN,CD,NN,NN,IN,JJ,JJ,JJ,JJ,JJ,NN,VBN,IN,JJ,JJ,NN,NN,.}","{2,0,0,6,6,2,6,11,11,11,2,0,18,18,18,18,18,11,18,0,24,24,24,19,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_55,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_56,"SUMMARY OF SECTIONS : lA entirely submitted 2A entirely submitted 3A entirely submitted 4A Vascular margin at the hilar region shaved 4B bronchial margin shaved 4C ? 4F tumor bisected 4G staple line margin 4H ? 4I non ? tumor parenchyma 4 ] lymph nodes 5A entirely submitted","{SUMMARY,OF,SECTIONS,:,lA,entirely,submitted,2A,entirely,submitted,3A,entirely,submitted,4A,Vascular,margin,at,the,hilar,region,shaved,4B,bronchial,margin,shaved,4C,?,4F,tumor,bisected,4G,staple,line,margin,4H,?,4I,non,?,tumor,parenchyma,4,],lymph,nodes,5A,entirely,submitted}","{summary,of,section,:,la,entirely,submit,2a,entirely,submit,3a,entirely,submit,4a,vascular,margin,at,the,hilar,region,shave,4b,bronchial,margin,shave,4c,?,4f,tumor,bisect,4g,staple,line,margin,4h,?,4us,non,?,tumor,parenchyma,4,],lymph,node,5a,entirely,submit}","{NN,IN,NNS,:,NN,RB,VBD,NN,RB,VBD,NN,RB,VBD,NN,JJ,NN,IN,DT,JJ,NN,VBD,NN,JJ,NN,VBD,NN,CD,NN,NN,VBN,NN,NN,NN,NN,NN,CD,NN,JJ,JJ,NN,NN,CD,NN,NN,NNS,NN,RB,VBD}","{0,0,1,0,7,7,1,10,10,7,13,13,10,16,16,27,0,20,20,16,16,25,25,22,13,31,31,31,27,31,35,40,37,35,40,38,48,44,44,44,40,48,48,48,1,51,51,48}","{}"
TCGA-97-8177, TCGA-97-8177SENT_57,"SPECIAL PROCEDURES : TTFl","{SPECIAL,PROCEDURES,:,TTFl}","{special,procedure,:,ttfl}","{JJ,NNS,:,NN}","{2,0,0,2}","{}"
TCGA-97-8177, TCGA-97-8177SENT_58,"Final Dia?nosis ierformed by","{Final,Dia?nosis,ierformed,by}","{final,dia?nosis,ierform,by}","{JJ,NN,VBN,IN}","{2,3,0,3}","{}"
TCGA-97-8177, TCGA-97-8177SENT_59,"ADDENDUM l :","{ADDENDUM,l,:}","{ADDENDUM,l,:}","{NNP,NN,:}","{2,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_60,"Visceral pleural invasion is not seen on an elastic stain .","{Visceral,pleural,invasion,is,not,seen,on,an,elastic,stain,.}","{visceral,pleural,invasion,be,not,see,on,a,elastic,stain,.}","{JJ,JJ,NN,VBZ,RB,VBN,IN,DT,JJ,VBP,.}","{3,3,10,6,6,3,0,9,6,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_61,"Addendum # 1 erformed by","{Addendum,#,1,erformed,by}","{Addendum,#,1,erform,by}","{NNP,#,CD,VBN,IN}","{0,3,1,1,4}","{}"
TCGA-97-8177, TCGA-97-8177SENT_62,"Electronically signed ?","{Electronically,signed,?}","{electronically,sign,?}","{RB,VBN,NN}","{2,0,2}","{}"
TCGA-97-8177, TCGA-97-8177SENT_63,"ADDENDUM # 2 :","{ADDENDUM,#,2,:}","{ADDENDUM,#,2,:}","{NNP,#,CD,:}","{0,3,1,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_64,"INTEGRATED ONCOLOGY EGFR Mutation Analisis Body Site : Lung","{INTEGRATED,ONCOLOGY,EGFR,Mutation,Analisis,Body,Site,:,Lung}","{integrate,ONCOLOGY,egfr,mutation,Analisis,Body,site,:,lung}","{VBN,NNP,NN,NN,NNP,NNP,NN,:,NN}","{0,6,6,6,6,7,1,0,1}","{}"
TCGA-97-8177, TCGA-97-8177SENT_65,"Clinical Data : Adenocarcinoma","{Clinical,Data,:,Adenocarcinoma}","{clinical,datum,:,adenocarcinoma}","{JJ,NNS,:,NN}","{2,0,0,2}","{}"
TCGA-97-8177, TCGA-97-8177SENT_66,"RESULTS : Positive for the L858R mutation in Exon 21 .","{RESULTS,:,Positive,for,the,L858R,mutation,in,Exon,21,.}","{result,:,positive,for,the,l858r,mutation,in,Exon,21,.}","{NNS,:,JJ,IN,DT,NN,NN,IN,NNP,CD,.}","{0,0,1,0,7,7,3,0,7,9,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_67,"INTERPRETATION : The L85 8R mutation is reported to correlate with responsiveness to EGFR tyrosine kinase inhibitor therapies in patients with non ? small ? cell lung carcinoma .","{INTERPRETATION,:,The,L85,8R,mutation,is,reported,to,correlate,with,responsiveness,to,EGFR,tyrosine,kinase,inhibitor,therapies,in,patients,with,non,?,small,?,cell,lung,carcinoma,.}","{interpretation,:,the,l85,8r,mutation,be,report,to,correlate,with,responsiveness,to,egfr,tyrosine,kinase,inhibitor,therapy,in,patient,with,non,?,small,?,cell,lung,carcinoma,.}","{NN,:,DT,NN,NN,NN,VBZ,VBN,TO,VB,IN,NN,TO,NN,NN,NN,NN,NNS,IN,NNS,IN,JJ,JJ,JJ,NN,NN,NN,NN,.}","{0,0,6,6,6,8,8,1,10,8,0,10,0,18,18,18,18,10,0,10,0,28,28,28,28,28,28,20,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_68,"COMMENT : Forty percent ( 40 % ) or more tumor cellularity is optimal for this mutation analysis .","{COMMENT,:,Forty,percent,(,40,%,),or,more,tumor,cellularity,is,optimal,for,this,mutation,analysis,.}","{COMMENT,:,forty,percent,(,40,%,),or,more,tumor,cellularity,be,optimal,for,this,mutation,analysis,.}","{NNP,:,CD,NN,CD,CD,NN,CD,CC,JJR,NN,NN,VBZ,JJ,IN,DT,NN,NN,.}","{0,0,4,14,7,7,4,4,0,8,12,8,14,1,0,18,18,14,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_69,"The sample submitted showed 8 % tumor cellularity upon pathologist review .","{The,sample,submitted,showed,8,%,tumor,cellularity,upon,pathologist,review,.}","{the,sample,submit,show,8,%,tumor,cellularity,upon,pathologist,review,.}","{DT,NN,VBN,VBD,CD,NN,NN,NN,IN,NN,NN,.}","{2,4,2,0,6,8,8,4,0,11,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_70,"A frequently occurring sequence change 2361G > A ( Q787Q ) was identified .","{A,frequently,occurring,sequence,change,2361G,>,A,(,Q787Q,),was,identified,.}","{a,frequently,occur,sequence,change,2361g,>,a,(,q787q,),be,identify,.}","{DT,RB,VBG,NN,NN,NN,JJR,DT,CD,NN,NN,VBD,VBN,.}","{6,3,6,6,6,0,6,11,11,11,13,13,7,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_71,"This polymorphism is known not to have clinical significance .","{This,polymorphism,is,known,not,to,have,clinical,significance,.}","{this,polymorphism,be,know,not,to,have,clinical,significance,.}","{DT,NN,VBZ,VBN,RB,TO,VB,JJ,NN,.}","{2,4,4,0,7,7,4,9,7,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_72,"Mutations in the tyrosine domain of the epidennal growth factor receptor ( EGFR ) gene are reported to be associated with differential responsiveness or resistance to EGFR tyrosine kinase inhibitor ( TKI ) therapies .","{Mutations,in,the,tyrosine,domain,of,the,epidennal,growth,factor,receptor,(,EGFR,),gene,are,reported,to,be,associated,with,differential,responsiveness,or,resistance,to,EGFR,tyrosine,kinase,inhibitor,(,TKI,),therapies,.}","{mutation,in,the,tyrosine,domain,of,the,epidennal,growth,factor,receptor,(,egfr,),gene,be,report,to,be,associate,with,differential,responsiveness,or,resistance,to,egfr,tyrosine,kinase,inhibitor,(,tkus,),therapy,.}","{NNS,IN,DT,NN,NN,IN,DT,JJ,NN,NN,NN,CD,NN,NN,NN,VBP,VBN,TO,VB,VBN,IN,JJ,NN,CC,NN,TO,NN,NN,NN,NN,NN,NN,CD,NNS,.}","{17,0,5,5,1,0,11,11,11,11,5,15,15,15,11,17,0,20,20,17,0,23,20,0,23,0,32,32,32,32,32,20,34,32,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_73,"The objective response rate among patients with a sensitizing mutation ranges from 55 to 82 % .","{The,objective,response,rate,among,patients,with,a,sensitizing,mutation,ranges,from,55,to,82,%,.}","{the,objective,response,rate,among,patient,with,a,sensitize,mutation,range,from,55,to,82,%,.}","{DT,JJ,NN,NN,IN,NNS,IN,DT,VBG,NN,NNS,IN,CD,TO,CD,NN,.}","{4,4,4,0,0,4,0,11,11,11,6,0,15,15,16,11,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_74,"This assay analyzes exons 18-21 of the EGFR tyrosine kinase domain ; based on the current literature most mutations in non ? small ? cell lung carcinoma ( NSCLC ) are expected to occur in these exons .","{This,assay,analyzes,exons,18-21,of,the,EGFR,tyrosine,kinase,domain,;,based,on,the,current,literature,most,mutations,in,non,?,small,?,cell,lung,carcinoma,(,NSCLC,),are,expected,to,occur,in,these,exons,.}","{this,assay,analyze,exon,18-21,of,the,egfr,tyrosine,kinase,domain,;,base,on,the,current,literature,most,mutation,in,non,?,small,?,cell,lung,carcinoma,(,nsclc,),be,expect,to,occur,in,these,exon,.}","{DT,NN,VBZ,NNS,CD,IN,DT,NN,NN,NN,NN,:,VBN,IN,DT,JJ,NN,JJS,NNS,IN,JJ,JJ,JJ,NN,NN,NN,NN,CD,NN,NN,VBP,VBN,TO,VB,IN,DT,NNS,.}","{2,3,0,3,4,0,11,11,11,11,4,0,0,33,17,17,33,20,17,0,28,28,28,28,28,28,20,31,31,33,33,3,35,33,0,38,35,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_75,"Mutations present in less than 10-20 % of extracted DNA may not be detected by this method .","{Mutations,present,in,less,than,10-20,%,of,extracted,DNA,may,not,be,detected,by,this,method,.}","{mutation,present,in,less,than,10-20,%,of,extract,dna,may,not,be,detect,by,this,method,.}","{NNS,JJ,IN,JJR,IN,CD,NN,IN,VBN,NN,MD,RB,VB,VBN,IN,DT,NN,.}","{14,1,0,5,6,7,2,0,10,7,14,14,14,0,0,17,14,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_76,"Mutation status in a sample may change during tumor progression or the course of therapy ; therefore this result can not be used to infer the presence or absence of a mutation in another sample or sub ? sample obtained from this tumor .","{Mutation,status,in,a,sample,may,change,during,tumor,progression,or,the,course,of,therapy,;,therefore,this,result,can,not,be,used,to,infer,the,presence,or,absence,of,a,mutation,in,another,sample,or,sub,?,sample,obtained,from,this,tumor,.}","{mutation,status,in,a,sample,may,change,during,tumor,progression,or,the,course,of,therapy,;,therefore,this,result,can,not,be,use,to,infer,the,presence,or,absence,of,a,mutation,in,another,sample,or,sub,?,sample,obtain,from,this,tumor,.}","{NN,NN,IN,DT,NN,MD,VB,IN,NN,NN,CC,DT,NN,IN,NN,:,RB,DT,NN,MD,RB,VB,VBN,TO,VB,DT,NN,CC,NN,IN,DT,NN,IN,DT,NN,CC,NN,CD,NN,VBN,IN,DT,NN,.}","{2,7,0,5,2,7,0,0,10,7,0,13,7,0,13,0,24,20,24,24,24,24,7,26,24,28,26,0,26,0,33,28,0,36,33,0,40,40,28,40,0,44,41,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_77,"This test is validated for non ? small cell lung carcinoma .","{This,test,is,validated,for,non,?,small,cell,lung,carcinoma,.}","{this,test,be,validate,for,non,?,small,cell,lung,carcinoma,.}","{DT,NN,VBZ,VBN,IN,JJ,JJ,JJ,NN,NN,NN,.}","{2,4,4,0,0,11,11,11,11,11,4,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_78,"The clinical significance and utility of this test in other tumor types is unknown .","{The,clinical,significance,and,utility,of,this,test,in,other,tumor,types,is,unknown,.}","{the,clinical,significance,and,utility,of,this,test,in,other,tumor,type,be,unknown,.}","{DT,JJ,NN,CC,NN,IN,DT,NN,IN,JJ,NN,NNS,VBZ,JJ,.}","{3,3,14,0,14,0,8,3,0,12,12,8,14,0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_79,"METHOD/LIMITATION : Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis .","{METHOD/LIMITATION,:,Tissue,sections,are,reviewed,by,a,pathologist,and,relevant,tumor,is,selected,for,analysis,.}","{METHOD/LIMITATION,:,tissue,section,be,review,by,a,pathologist,and,relevant,tumor,be,select,for,analysis,.}","{NNP,:,NN,NNS,VBP,VBN,IN,DT,NN,CC,JJ,NN,VBZ,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,0,12,14,14,1,0,14,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_80,"DNA is isolated from the samples quantified and amplified by polymerase chain reaction ( PCR ) using primers to exons 18-21 of the EGFR gene .","{DNA,is,isolated,from,the,samples,quantified,and,amplified,by,polymerase,chain,reaction,(,PCR,),using,primers,to,exons,18-21,of,the,EGFR,gene,.}","{dna,be,isolate,from,the,sample,quantify,and,amplify,by,polymerase,chain,reaction,(,pcr,),use,primer,to,exon,18-21,of,the,egfr,gene,.}","{NN,VBZ,VBN,IN,DT,NNS,VBN,CC,VBN,IN,NN,NN,NN,CD,NN,NN,VBG,NNS,TO,NNS,CD,IN,DT,NN,NN,.}","{8,3,0,0,6,3,3,0,3,0,17,17,17,17,17,10,17,18,0,18,21,0,26,26,21,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_81,"PCR products are analyzed by bi ? directional direct DNA sequencing using capillary gel electrophoresis and ?uorescence detection .","{PCR,products,are,analyzed,by,bi,?,directional,direct,DNA,sequencing,using,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{pcr,product,be,analyze,by,bus,?,directional,direct,dna,sequencing,use,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{NN,NNS,VBP,VBN,IN,NN,CD,JJ,JJ,NN,NN,VBG,JJ,NN,NN,CC,NN,NN,.}","{2,4,4,0,0,4,11,11,11,11,4,11,15,15,12,0,18,12,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_82,"False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample .","{False,positive,or,negative,results,may,occur,for,reasons,that,include,genetic,variants,or,somatic,heterogeneity,of,the,tissue,sample,.}","{false,positive,or,negative,result,may,occur,for,reason,that,include,genetic,variant,or,somatic,heterogeneity,of,the,tissue,sample,.}","{JJ,JJ,CC,JJ,NNS,MD,VB,IN,NNS,WDT,VBP,JJ,NNS,CC,JJ,NN,IN,DT,NN,NN,.}","{5,5,0,2,7,7,0,0,7,11,9,13,11,0,16,11,0,20,20,16,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_83,"REFERENCES : DISCLAIMER : The test was deVelo ed and its erfonnance characteristics detennined by LLC .","{REFERENCES,:,DISCLAIMER,:,The,test,was,deVelo,ed,and,its,erfonnance,characteristics,detennined,by,LLC,.}","{reference,:,DISCLAIMER,:,the,test,be,deVelo,ed,and,its,erfonnance,characteristic,detennine,by,LLC,.}","{NNS,:,NNP,:,DT,NN,VBD,NNP,VBD,CC,PRP$,NN,NNS,VBN,IN,NNP,.}","{0,0,1,0,6,8,8,1,8,0,13,13,8,13,0,14,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_84,"The laboratory is re ulated under the Clinical Laboratory Improvement Amendments of","{The,laboratory,is,re,ulated,under,the,Clinical,Laboratory,Improvement,Amendments,of}","{the,laboratory,be,re,ulate,under,the,clinical,laboratory,improvement,amendment,of}","{DT,NN,VBZ,JJ,VBN,IN,DT,JJ,NN,NN,NNS,IN}","{2,4,4,0,4,0,11,11,11,11,5,11}","{}"
TCGA-97-8177, TCGA-97-8177SENT_85,"( CLIA ) as qualified to perfonn high complexity clinical testing .","{(,CLIA,),as,qualified,to,perfonn,high,complexity,clinical,testing,.}","{(,clium,),as,qualify,to,perfonn,high,complexity,clinical,testing,.}","{RB,NN,RB,IN,VBN,TO,VB,JJ,NN,JJ,NN,.}","{2,0,2,0,11,7,5,9,7,11,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_86,"This particular test is not considered a stand alone test and should be used only in the context of other diagnostic tests or clinical work ? up related to treatment decisions .","{This,particular,test,is,not,considered,a,stand,alone,test,and,should,be,used,only,in,the,context,of,other,diagnostic,tests,or,clinical,work,?,up,related,to,treatment,decisions,.}","{this,particular,test,be,not,consider,a,stand,alone,test,and,should,be,use,only,in,the,context,of,other,diagnostic,test,or,clinical,work,?,up,related,to,treatment,decision,.}","{DT,JJ,NN,VBZ,RB,VBN,DT,NN,RB,NN,CC,MD,VB,VBN,RB,IN,DT,NN,IN,JJ,JJ,NNS,CC,JJ,NN,RB,RB,JJ,TO,NN,NNS,.}","{3,3,14,6,6,0,10,10,10,6,0,14,14,6,14,0,18,14,0,22,22,18,0,25,27,25,28,14,0,31,28,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_87,"Addendum # 2 erformed by ADDENDUM # 3 :","{Addendum,#,2,erformed,by,ADDENDUM,#,3,:}","{Addendum,#,2,erform,by,ADDENDUM,#,3,:}","{NNP,#,CD,VBN,IN,NNP,#,CD,:}","{0,3,1,1,0,4,8,6,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_88,"INTEGRATED ONCOLOGY MOLECULAR ONCOLOGY KRAS MUTATION ANALYSIS","{INTEGRATED,ONCOLOGY,MOLECULAR,ONCOLOGY,KRAS,MUTATION,ANALYSIS}","{integrate,ONCOLOGY,MOLECULAR,ONCOLOGY,KRAS,MUTATION,ANALYSIS}","{VBN,NNP,NNP,NNP,NNP,NNP,NNP}","{0,7,7,7,7,7,1}","{}"
TCGA-97-8177, TCGA-97-8177SENT_89,"Body Site : Lung Clinical Data : Adenocarcinoma","{Body,Site,:,Lung,Clinical,Data,:,Adenocarcinoma}","{body,site,:,lung,clinical,datum,:,adenocarcinoma}","{NN,NN,:,NN,JJ,NNS,:,NN}","{0,1,0,6,6,1,0,6}","{}"
TCGA-97-8177, TCGA-97-8177SENT_90,"RESULTS : Wild ? type gene .","{RESULTS,:,Wild,?,type,gene,.}","{result,:,Wild,?,type,gene,.}","{NNS,:,NNP,CD,NN,NN,.}","{0,0,1,6,6,3,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_91,"INTERPRETATION : No mutations were identified at codons l2 and 13 of the KRAS gene .","{INTERPRETATION,:,No,mutations,were,identified,at,codons,l2,and,13,of,the,KRAS,gene,.}","{interpretation,:,no,mutation,be,identify,at,codon,l2,and,13,of,the,KRAS,gene,.}","{NN,:,DT,NNS,VBD,VBN,IN,NNS,NN,CC,CD,IN,DT,NNP,NN,.}","{0,0,4,6,6,1,0,9,6,0,6,0,15,15,11,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_92,"COMMENT : Mutations in the KRAS gene are reported to be associated with poor prognosis and resistance to targeted tyrosine kinase inhibitor therapies in patients with non ? small ? cell lung cancer ( NSCLC ) .","{COMMENT,:,Mutations,in,the,KRAS,gene,are,reported,to,be,associated,with,poor,prognosis,and,resistance,to,targeted,tyrosine,kinase,inhibitor,therapies,in,patients,with,non,?,small,?,cell,lung,cancer,(,NSCLC,),.}","{COMMENT,:,mutation,in,the,KRAS,gene,be,report,to,be,associate,with,poor,prognosis,and,resistance,to,target,tyrosine,kinase,inhibitor,therapy,in,patient,with,non,?,small,?,cell,lung,cancer,(,nsclc,),.}","{NNP,:,NNS,IN,DT,NNP,NN,VBP,VBN,TO,VB,VBN,IN,JJ,NN,CC,NN,TO,VBN,NN,NN,NN,NNS,IN,NNS,IN,JJ,JJ,JJ,NN,NN,NN,NN,CD,NN,NN,.}","{0,0,9,0,7,7,3,9,1,12,12,9,0,15,12,0,12,0,37,24,24,24,20,0,24,0,36,36,36,36,36,36,36,36,26,12,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_93,"KRAS mutations occur in 15-30 % of non ? small ? cell lung cancer ( NSCLC ) patients and are strongly associated with adenocarcinoma and smoking history .","{KRAS,mutations,occur,in,15-30,%,of,non,?,small,?,cell,lung,cancer,(,NSCLC,),patients,and,are,strongly,associated,with,adenocarcinoma,and,smoking,history,.}","{KRAS,mutation,occur,in,15-30,%,of,non,?,small,?,cell,lung,cancer,(,nsclc,),patient,and,be,strongly,associate,with,adenocarcinoma,and,smoking,history,.}","{NNP,NNS,VBP,IN,CD,NN,IN,JJ,JJ,JJ,NN,NN,NN,NN,CD,NN,CD,NNS,CC,VBP,RB,VBN,IN,NN,CC,NN,NN,.}","{2,3,0,0,6,3,0,16,16,16,16,16,16,16,16,6,18,3,0,22,22,3,0,27,0,24,22,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_94,"This assay analyzes codons l2 and 13 in exon 2 of the KRAS gene ; based on the current literature approximately 98 % of mutations are expected to occur in these codons .","{This,assay,analyzes,codons,l2,and,13,in,exon,2,of,the,KRAS,gene,;,based,on,the,current,literature,approximately,98,%,of,mutations,are,expected,to,occur,in,these,codons,.}","{this,assay,analyze,codon,l2,and,13,in,exon,2,of,the,KRAS,gene,;,base,on,the,current,literature,approximately,98,%,of,mutation,be,expect,to,occur,in,these,codon,.}","{DT,NN,VBZ,NNS,NN,CC,CD,IN,NN,CD,IN,DT,NNP,NN,:,VBN,IN,DT,JJ,NN,RB,CD,NN,IN,NNS,VBP,VBN,TO,VB,IN,DT,NNS,.}","{2,3,0,5,3,0,5,0,3,9,0,14,14,9,0,0,28,20,20,28,23,24,28,0,24,28,3,30,28,0,33,30,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_95,"The analytical sensitivity of the assay is approximately 10 % ; thus mutations present in a low percentage of cells may not be detected .","{The,analytical,sensitivity,of,the,assay,is,approximately,10,%,;,thus,mutations,present,in,a,low,percentage,of,cells,may,not,be,detected,.}","{the,analytical,sensitivity,of,the,assay,be,approximately,10,%,;,thus,mutation,present,in,a,low,percentage,of,cell,may,not,be,detect,.}","{DT,JJ,NN,IN,DT,NN,VBZ,RB,CD,NN,:,RB,NNS,JJ,IN,DT,JJ,NN,IN,NNS,MD,RB,VB,VBN,.}","{3,3,10,0,6,3,10,9,10,0,0,24,24,13,0,18,18,14,0,18,24,24,24,10,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_96,"This test is validated for use in identifying KRAS codon 12 and codon 13 mutations in fresh frozen or fonnalin ? fixed paraffin embedded tissue .","{This,test,is,validated,for,use,in,identifying,KRAS,codon,12,and,codon,13,mutations,in,fresh,frozen,or,fonnalin,?,fixed,paraffin,embedded,tissue,.}","{this,test,be,validate,for,use,in,identify,KRAS,codon,12,and,codon,13,mutation,in,fresh,frozen,or,fonnalin,?,fix,paraffin,embedded,tissue,.}","{DT,NN,VBZ,VBN,IN,NN,IN,VBG,NNP,NN,CD,CC,NN,CD,NNS,IN,JJ,JJ,CC,NN,NN,VBN,NN,JJ,NN,.}","{2,4,4,0,0,4,0,4,10,15,10,0,10,15,8,0,19,15,0,23,15,15,27,27,24,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_97,"In particular the test performance has been established in samples of colorectal cancer and non ? small cell lung carcinoma which harbor these mutations although several other tissues are also known to harbor KRAS mutations ( e.g. tumors of pancreas bile duct ovary appendix etc. ) .","{In,particular,the,test,performance,has,been,established,in,samples,of,colorectal,cancer,and,non,?,small,cell,lung,carcinoma,which,harbor,these,mutations,although,several,other,tissues,are,also,known,to,harbor,KRAS,mutations,(,e.g.,tumors,of,pancreas,bile,duct,ovary,appendix,etc.,),.}","{in,particular,the,test,performance,have,be,establish,in,sample,of,colorectal,cancer,and,non,?,small,cell,lung,carcinoma,which,harbor,these,mutation,although,several,other,tissue,be,also,know,to,harbor,KRAS,mutation,(,e.g.,tumor,of,pancreas,bile,duct,ovary,appendix,etc.,),.}","{IN,JJ,DT,NN,NN,VBZ,VBN,VBN,IN,NNS,IN,JJ,NN,CC,JJ,JJ,JJ,NN,NN,NN,WDT,VBP,DT,NNS,IN,JJ,JJ,NNS,VBP,RB,VBN,TO,VB,NNP,NNS,CD,FW,NNS,IN,NN,NN,NN,NN,NN,FW,FW,.}","{0,8,5,5,8,8,8,0,0,8,0,13,10,0,20,20,20,20,20,10,22,20,24,22,32,29,29,32,32,32,8,34,32,36,39,39,39,34,0,39,44,41,41,41,51,41,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_98,"Analysis of EGFR mutation or gene amplification status may provide additional infonnation regarding this patient 's probability of response to targeted tyrosine kinase inhibitor therapies if clinically indicated .","{Analysis,of,EGFR,mutation,or,gene,amplification,status,may,provide,additional,infonnation,regarding,this,patient,'s,probability,of,response,to,targeted,tyrosine,kinase,inhibitor,therapies,if,clinically,indicated,.}","{analysis,of,egfr,mutation,or,gene,amplification,status,may,provide,additional,infonnation,regard,this,patient,'s,probability,of,response,to,target,tyrosine,kinase,inhibitor,therapy,if,clinically,indicate,.}","{NN,IN,NN,NN,CC,NN,NN,NN,MD,VB,JJ,NN,VBG,DT,NN,POS,NN,IN,NN,TO,VBN,NN,NN,NN,NNS,IN,RB,VBN,.}","{10,0,4,1,0,8,8,4,10,0,12,10,0,15,17,0,12,0,17,0,10,25,25,25,21,29,29,21,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_99,"See references .","{See,references,.}","{see,reference,.}","{VB,NNS,.}","{0,1,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_100,"METHOD/LIMITATIONS : Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis .","{METHOD/LIMITATIONS,:,Tissue,sections,are,reviewed,by,a,pathologist,and,relevant,tumor,is,selected,for,analysis,.}","{METHOD/LIMITATIONS,:,tissue,section,be,review,by,a,pathologist,and,relevant,tumor,be,select,for,analysis,.}","{NNP,:,NN,NNS,VBP,VBN,IN,DT,NN,CC,JJ,NN,VBZ,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,0,12,14,14,1,0,14,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_101,"DNA is isolated from the sample quantified and amplified by polymerase chain reaction ( PCR ) using primers to exon 2 of the KRAS gene .","{DNA,is,isolated,from,the,sample,quantified,and,amplified,by,polymerase,chain,reaction,(,PCR,),using,primers,to,exon,2,of,the,KRAS,gene,.}","{dna,be,isolate,from,the,sample,quantify,and,amplify,by,polymerase,chain,reaction,(,pcr,),use,primer,to,exon,2,of,the,KRAS,gene,.}","{NN,VBZ,VBN,IN,DT,NN,VBN,CC,VBN,IN,NN,NN,NN,CD,NN,NN,VBG,NNS,TO,NN,CD,IN,DT,NNP,NN,.}","{8,3,0,0,6,3,3,0,3,0,17,17,17,17,17,10,17,18,0,18,21,0,26,26,21,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_102,"PCR products are subjected to single nucleotide primer extension to detect mutations at codons l2 and I3 ; primer extension products are analyzed using capillary gel electrophoresis and ?uorescence detection .","{PCR,products,are,subjected,to,single,nucleotide,primer,extension,to,detect,mutations,at,codons,l2,and,I3,;,primer,extension,products,are,analyzed,using,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{pcr,product,be,subject,to,single,nucleotide,primer,extension,to,detect,mutation,at,codon,l2,and,i3,;,primer,extension,product,be,analyze,use,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{NN,NNS,VBP,VBN,TO,JJ,NN,NN,NN,TO,VB,NNS,IN,NNS,NN,CC,NN,:,NN,NN,NNS,VBP,VBN,VBG,JJ,NN,NN,CC,NN,NN,.}","{2,4,4,0,0,9,9,9,4,11,4,11,0,15,11,0,11,0,21,21,23,23,4,23,27,27,24,0,30,27,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_103,"False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample .","{False,positive,or,negative,results,may,occur,for,reasons,that,include,genetic,variants,or,somatic,heterogeneity,of,the,tissue,sample,.}","{false,positive,or,negative,result,may,occur,for,reason,that,include,genetic,variant,or,somatic,heterogeneity,of,the,tissue,sample,.}","{JJ,JJ,CC,JJ,NNS,MD,VB,IN,NNS,WDT,VBP,JJ,NNS,CC,JJ,NN,IN,DT,NN,NN,.}","{5,5,0,2,7,7,0,0,7,11,9,13,11,0,16,11,0,20,20,16,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_104,"The test was develo ed and its erfonnance characteristics re ulated under the Clinical Laboratory Improvement Amendments of","{The,test,was,develo,ed,and,its,erfonnance,characteristics,re,ulated,under,the,Clinical,Laboratory,Improvement,Amendments,of}","{the,test,be,develo,ed,and,its,erfonnance,characteristic,re,ulate,under,the,clinical,laboratory,improvement,amendment,of}","{DT,NN,VBD,JJ,NN,CC,PRP$,NN,NNS,VBP,VBN,IN,DT,JJ,NN,NN,NNS,IN}","{2,5,5,5,0,0,9,9,10,5,10,0,17,17,17,17,11,17}","{}"
TCGA-97-8177, TCGA-97-8177SENT_105,"( CLIA ) as qualified to perfonn high complexity clinical testing .","{(,CLIA,),as,qualified,to,perfonn,high,complexity,clinical,testing,.}","{(,clium,),as,qualify,to,perfonn,high,complexity,clinical,testing,.}","{RB,NN,RB,IN,VBN,TO,VB,JJ,NN,JJ,NN,.}","{2,0,2,0,11,7,5,9,7,11,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_106,"This particular test is not considered a stand alone test and should be used only in the context of other dia nostic tests or clinical work ? up related to treatment decisions .","{This,particular,test,is,not,considered,a,stand,alone,test,and,should,be,used,only,in,the,context,of,other,dia,nostic,tests,or,clinical,work,?,up,related,to,treatment,decisions,.}","{this,particular,test,be,not,consider,a,stand,alone,test,and,should,be,use,only,in,the,context,of,other,dium,nostic,test,or,clinical,work,?,up,related,to,treatment,decision,.}","{DT,JJ,NN,VBZ,RB,VBN,DT,NN,RB,NN,CC,MD,VB,VBN,RB,IN,DT,NN,IN,JJ,NN,JJ,NNS,CC,JJ,NN,RB,RB,JJ,TO,NN,NNS,.}","{3,3,14,6,6,0,10,10,10,6,0,14,14,6,14,0,18,14,0,21,18,23,6,0,26,28,26,29,6,0,32,29,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_107,"? is a business unit of wholli ? owned subsidiary of","{?,is,a,business,unit,of,wholli,?,owned,subsidiary,of}","{?,be,a,business,unit,of,wholli,?,own,subsidiary,of}","{NN,VBZ,DT,NN,NN,IN,JJ,NN,VBN,NN,IN}","{5,5,5,5,0,0,8,5,8,9,10}","{}"
TCGA-97-8177, TCGA-97-8177SENT_108,"Electronicalli siined by :","{Electronicalli,siined,by,:}","{electronicalli,siin,by,:}","{JJ,VBN,IN,:}","{0,1,2,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_109,"Date :","{Date,:}","{date,:}","{NN,:}","{0,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_110,"Addendum # 3 ierformed by The electronic signature attests that the named Attending Pathologist has evaluated the specimen referred to in the signed section of the report and fonnulated the diagnosis therein .","{Addendum,#,3,ierformed,by,The,electronic,signature,attests,that,the,named,Attending,Pathologist,has,evaluated,the,specimen,referred,to,in,the,signed,section,of,the,report,and,fonnulated,the,diagnosis,therein,.}","{Addendum,#,3,ierform,by,the,electronic,signature,attest,that,the,name,attend,pathologist,have,evaluate,the,specimen,refer,to,in,the,sign,section,of,the,report,and,fonnulate,the,diagnosis,therein,.}","{NNP,#,CD,VBN,IN,DT,JJ,NN,VBZ,IN,DT,VBN,VBG,NN,VBZ,VBN,DT,NN,VBD,TO,IN,DT,VBN,NN,IN,DT,NN,CC,VBD,DT,NN,RB,.}","{19,3,9,3,0,8,8,4,1,16,16,11,12,13,16,9,18,16,0,19,0,24,24,19,0,27,24,0,19,31,29,29,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_111,"This report may include one or more immunohistochemical stain results that use analyte specific reagents .","{This,report,may,include,one,or,more,immunohistochemical,stain,results,that,use,analyte,specific,reagents,.}","{this,report,may,include,one,or,more,immunohistochemical,stain,result,that,use,analyte,specific,reagent,.}","{DT,NN,MD,VB,CD,CC,JJR,JJ,VB,NNS,WDT,VBP,NN,JJ,NNS,.}","{2,4,4,0,8,0,8,9,4,9,12,10,15,15,12,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_112,"The tests were developed and their performance characteristics detennined by ] Department of Pathology .","{The,tests,were,developed,and,their,performance,characteristics,detennined,by,],Department,of,Pathology,.}","{the,test,be,develop,and,they,performance,characteristic,detennine,by,],Department,of,Pathology,.}","{DT,NNS,VBD,VBN,CC,PRP$,NN,NNS,VBN,IN,NNP,NNP,IN,NNP,.}","{2,4,4,0,0,8,8,9,4,0,12,9,0,12,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_113,"They have not been cleared or approved by the US Food and Drug Administration .","{They,have,not,been,cleared,or,approved,by,the,US,Food,and,Drug,Administration,.}","{they,have,not,be,clear,or,approve,by,the,US,Food,and,Drug,Administration,.}","{PRP,VBP,RB,VBN,VBN,CC,VBN,IN,DT,NNP,NNP,CC,NNP,NNP,.}","{7,5,5,5,0,0,5,0,11,11,5,0,14,5,0}","{}"
TCGA-97-8177, TCGA-97-8177SENT_114,"The FDA has detennined that such clearance or approval is not necessary .","{The,FDA,has,detennined,that,such,clearance,or,approval,is,not,necessary,.}","{the,FDA,have,detennine,that,such,clearance,or,approval,be,not,necessary,.}","{DT,NNP,VBZ,VBN,IN,JJ,NN,CC,NN,VBZ,RB,JJ,.}","{2,4,4,0,12,7,12,0,7,12,12,4,0}","{}"
